Diabetic Retinopathy Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | Key Players - Genentech, Regeneron, Roche, Opthea, Regenxbio, Ocuphire, Eisai, Apexian, Oculis, Bayer, Novartis, Allegro

DelveInsight's "Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast 2032" report provides comprehensive insights into the disease landscape, encompassing historical and forecasted epidemiological data, along with an analysis of the Diabetic Retinopathy market. The report offers valuable information regarding market size, share, emerging trends, and growth prospects across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Additionally, the report delves into emerging therapies for Diabetic Retinopathy, providing insights into current treatment methodologies, individual therapy market shares, and a comprehensive evaluation of the market size, spanning from 2019 to 2032. It assesses the existing treatment practices and algorithms for Diabetic Retinopathy, investigates the key factors influencing market growth, identifies barriers, and highlights unmet medical needs. This comprehensive analysis aims to pinpoint opportunities and gauge the market's inherent potential to address the critical aspects of Diabetic Retinopathy management.

Learn How the Diabetic Retinopathy Market is Evolving with the Ongoing Developments @ Diabetic Retinopathy Market Outlook and Developments

Diabetic Retinopathy: An Overview

Diabetic Retinopathy (DR) is a microvascular disorder occurring due to the long-term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic Retinopathy affects people with diagnosed or undiagnosed diabetes mellitus. The propensity of developing Diabetic Retinopathy is directly proportional to the age of the patient and the duration of diabetes, as well as to poor glycemic control and fluctuating blood pressure levels.

Chronic hyperglycemia is considered as a primary pathogenic agent in Diabetic Retinopathy. The morphological changes seen in small retinal vessels in Diabetic Retinopathy include early loss of pericytes, basement membrane thickening, loss of endothelial cells, increased vascular permeability, platelet aggregation, leukocytosis, and capillary dropout.

Diabetic Retinopathy develops in stages over time, including, background retinopathy, pre-proliferative retinopathy, and proliferative retinopathy. Diagnosis of Diabetic Retinopathy is done by a comprehensive dilated eye exam. Several diagnostic tests like Fluorescein angiography and optical coherence tomography (OCT) are done to look for abnormalities in the inside and outside parts of the eyes.

Treatment options for curing Diabetes Retinopathy include anti-VEGF medications (Lucentis, Eylea, and others), Laser treatment, and Eye Surgery. People with uncontrolled diabetes have a higher risk of developing eye problems that look similar to Diabetic Retinopathy like, Macular edema.

Diabetic Retinopathy Market Key Facts

• The total prevalent cases of Diabetic Retinopathy in the 7MM were 12,585,000+ in 2021.
• According to secondary research by analysts at DelveInsight, it is estimated that the prevalence of Diabetic Retinopathy is slightly higher in males as compared to females.
• According to a meta-analysis on the Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045 by Teo et al., (2021), there are approximately 93 million patients suffering from Diabetic Retinopathy, 17 million patients with proliferative Diabetic Retinopathy, and 21 million patients with diabetic macular edema, worldwide. These data highlight the significant global public health burden of Diabetic Retinopathy.

Learn More About the Major Trends and Dynamics Shaping the Market Growth @ Diabetic Retinopathy Therapeutics Market Analysis

Diabetic Retinopathy Therapeutics Analysis

Current treatments for diabetic retinopathies are limited, and the focus relies heavily on the presence of macular edema. Historically, traditional therapies such as vitrectomy, photocoagulation, and corticosteroids were used. These offer no opportunity for vision improvement and come with high rates of complications.

On the other hand, Anti-vascular endothelial growth factor (anti-VEGF) drugs have made a meaningful improvement to DME sufferers over the past decade, but even these have limited to no success in third or more sufferers. Three anti-VEGF drugs are preferred as the first line of therapy. They work by blocking the production of new blood vessels and reducing macular swelling. This slows vision loss and improves vision. These agents are administered via injections into the eye. These include aflibercept (EYLEA from Regeneron and Bayer), ranibizumab (LUCENTIS from Genentech and Novartis), and bevacizumab (AVASTIN from Genentech); these dominate the Diabetic Retinopathy market.

Several major pharma and biotech companies are developing therapies for Diabetic Retinopathy. Currently, Kodiak Sciences is leading the therapeutics market with its Diabetic Retinopathy drug candidates in the most advanced stage of clinical development.

Diabetic Retinopathy Therapeutic Advancements and Emerging Treatments:

• Diabetic Retinopathy Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd., and others, are actively engaged in developing novel drugs for potential market entry.
• Diabetic Retinopathy Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Diabetic Retinopathy. Some of the emerging therapies in the pipeline include Brolucizumab: Novartis Pharmaceuticals; LKA651: Novartis Pharmaceuticals; Risuteganib: Allegro Ophthalmics LLC; ADVM-022: Adverum Biotechnologies Inc.; Brolucizumab: Novartis; OTT-166: OcuTerra Therapeutics; OTX-TKI: Ocular Therapeutix, and others.

Diabetic Retinopathy Market Growth Factors

The Diabetic Retinopathy market is poised for substantial growth in the coming years, primarily driven by several key factors. Technological advancements in diagnostic tools and treatment options are set to revolutionize disease management, enabling earlier detection and intervention. Moreover, the rising global prevalence of diabetes, a significant risk factor for Diabetic Retinopathy, is anticipated to fuel market expansion. Healthcare awareness campaigns, coupled with increasing investments in the healthcare sector, are likely to enhance patient access to screening and treatment services. 

Additionally, collaborations between pharmaceutical companies and research institutions, aimed at developing innovative therapies and personalized medicine approaches, are expected to further propel market growth. Overall, these converging factors present a promising landscape for the Diabetic Retinopathy market, fostering advancements that could significantly improve patient outcomes and quality of life.

Diabetic Retinopathy Market 

The report's market outlook section offers a comprehensive understanding of the historical, present, and projected market size. It scrutinizes the influence of existing and upcoming pipeline therapies for Diabetic Retinopathy. Moreover, it conducts a thorough evaluation of the factors driving and hindering the Diabetic Retinopathy market, highlighting unmet needs and emerging technologies poised to shape the market's dynamics in the foreseeable future.

The report meticulously outlines the market trends concerning each marketed Diabetic Retinopathy drug and mid to late-stage pipeline therapies. This evaluation gauges their impact by considering various aspects such as the annual cost of therapy, Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competitive landscape among therapies, brand value, and their collective influence on the market dynamics.

Discover the Anticipated Evolution and Growth of the Market @ Diabetic Retinopathy Therapeutic Market Forecast

Diabetic Retinopathy Epidemiology Assessment 

The epidemiology section offers valuable insights into the historical, present, and anticipated trends in Diabetic Retinopathy epidemiology across the seven major countries (7MM) from 2019 to 2032. This section aims to identify the factors contributing to current and projected Diabetic Retinopathy epidemiological patterns by examining diverse studies and research findings. Additionally, it furnishes a comprehensive analysis of diagnosed and prevalent patient populations, and future projections, and incorporates perspectives from key opinion leaders to enrich the understanding of this disease landscape.

The Report Covers the Diabetic Retinopathy Epidemiology, Segmented as -

• Total Prevalent Cases of Diabetic Retinopathy
• Gender-specific Diabetic Retinopathy
• Severity-specific Cases of Diabetic Retinopathy
• Age-specific Cases of Diabetic Retinopathy

Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities

The drug uptake section concentrates on evaluating the adoption rate of newly launched or upcoming potential drugs within the Diabetic Retinopathy market during the study period. This analysis encompasses the assessment of drug uptake in the Diabetic Retinopathy market, patient adoption across different therapies, and the sales performance of each drug. Furthermore, the therapeutics assessment section facilitates a comprehensive comprehension of market dynamics by examining drug sales trends, identifying drugs with the highest adoption rates, and elucidating the reasons contributing to the widespread use of specific medications. Additionally, it conducts comparative analyses among Diabetic Retinopathy drugs, considering their sales performance and respective market shares.

The report encompasses comprehensive coverage of ongoing Diabetic Retinopathy pipeline development initiatives. It furnishes valuable insights into diverse therapeutic candidates at various developmental stages, elucidating the significant companies actively engaged in creating targeted treatments for Diabetic Retinopathy. Moreover, it conducts an in-depth analysis of recent advancements, including collaborations, acquisitions, mergers, licensing details, and patent information, providing a holistic view of emerging therapies within the field.

For in-depth insights and detailed TOC, download the sample report @ Diabetic Retinopathy Market Outlook and Forecast

Related Reports:

Diabetic Retinopathy Epidemiology Forecast

Diabetic Retinopathy Epidemiology Forecast report delivers an in-depth understanding of Diabetic Retinopathy, and historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diabetic Retinopathy Pipeline Insight

The Diabetic Retinopathy Pipeline Insight report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Healthcare Consulting and Market Research Services by DelveInsight

Unlock key insights and innovation in the healthcare industry with our cutting-edge market research services, paving the way for informed decisions and competitive advantage in this rapidly evolving industry @ Medical Device Consulting Services

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

 Contact Information:

Shruti Thakur

info@delveinsight.com

+1(919)321-6187

www.delveinsight.com

 Connect with DelveInsight: LinkedIn | Facebook | Twitter